Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 364

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 364
---
 ended September 30, 2025, the Company sold 253,682shares of common stock of the Company for net proceeds of $ 1,278,217under the July 2025 Keystone Purchase Agreement. Issuance of Common Stock to Arena Business Solutions Global SPC II, Ltd. (“Arena”) for the Arena ELOC On February 23, 2024, the Company entered into a common stock purchase agreement (the “Arena Purchase Agreement”) with Arena, pursuant to which we may sell and issue, and Arena is obligated to purchase, up to $ 25,000,000of Common Stock. The price of the shares purchased by Arena under the ELOC is 90% of various VWAP and closing price-based formulae, and requires a waiver, should the selling price be below $ 500.00per share. As consideration for Arena commitment to purchase shares of Common Stock pursuant to the Arena Purchase Agreement, in May 2024, the Company issued 173shares of Common Stock to Arena valued at $ 500,000, which is reflected as deferred offering costs on the accompanying consolidated balance sheet as of December 31, 2024. The Company has sold noshares of Common Stock to Arena under the Arena ELOC during the nine months ended September 30, 2025 and 2024. As of September 30, 2025, the Company wrote off the deferred offering costs of $ 500,000since the likelihood of raising funds pursuant to the Arena Purchase Agreement is unlikely. Accordingly, during the three and nine months ended September 30, 2025, the Company recorded a write off of deferred offering costs of $ 500,000, which is reflected in other income (expenses) on the accompanying unaudited condensed statements of operations. Sale of Pre-funded Warrants and Common Stock On February 5, 2025, the Company announced the pricing of a reasonable best efforts public offering (the “Offering”), with participation from a member of the Company’s board of directors and a single institutional investor, for the purchase and sale of (i) 127,551shares of Common Stock or common stock equivalents in lieu thereof (the Company sold 15,000shares of its common stock and 112,551pre-funded warrants); and (ii) common warrants to purchase up to 127,551shares of common stock (the “Warrants”), at a combined public offering price of $ 39.20per share and Warrant. In connection with the Offering